Mavoglurant is under clinical development by Stalicla and currently in Phase II for Substance (Drug) Abuse. According to GlobalData, Phase II drugs for Substance (Drug) Abuse have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mavoglurant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mavoglurant is under development for the treatment of cocaine use disorder and for language learning in young children with fragile X syndrome (FXS). The drug candidate is administered orally. It targets a metabotropic glutamate receptor 5 (mGluR5).
It was also under development for the treatment of the obsessive compulsive disorder (OCD), chorea in Huntington's disease, moderate to severe L-dopa induced dyskinesia, gastroesophageal reflux disease and smoking cessation.
Stalicla is a biotechnology company developing precision medicine treatments for patients with Neurodevelopmental disorders. Stalicla is headquartered in Geneva, Switzerland.
For a complete picture of Mavoglurant’s drug-specific PTSR and LoA scores, buy the report here.